Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVTA NASDAQ:OPGN NASDAQ:PBLA NASDAQ:TTOO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsOPGNOpGen$2.58$0.00▼$0.00$1K-1.77596 shs21 shsPBLAPanbela Therapeutics$0.05$0.16$0.01▼$0.47$243K1.3316,058 shsN/ATTOOT2 Biosystems$0.01+1.8%$0.04$0.00▼$2.66$118K0.19472,856 shs6,595 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVTAInvitae0.00%0.00%0.00%0.00%0.00%OPGNOpGen0.00%0.00%0.00%-100.00%-100.00%PBLAPanbela Therapeutics0.00%-66.67%-68.33%-83.33%-85.71%TTOOT2 Biosystems+1.82%-49.09%-49.09%-96.08%-99.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsOPGNOpGen$2.58$0.00▼$0.00$1K-1.77596 shs21 shsPBLAPanbela Therapeutics$0.05$0.16$0.01▼$0.47$243K1.3316,058 shsN/ATTOOT2 Biosystems$0.01+1.8%$0.04$0.00▼$2.66$118K0.19472,856 shs6,595 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVTAInvitae0.00%0.00%0.00%0.00%0.00%OPGNOpGen0.00%0.00%0.00%-100.00%-100.00%PBLAPanbela Therapeutics0.00%-66.67%-68.33%-83.33%-85.71%TTOOT2 Biosystems+1.82%-49.09%-49.09%-96.08%-99.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVTAInvitae 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/APBLAPanbela Therapeutics 0.00N/AN/AN/ATTOOT2 Biosystems 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00OPGNOpGen$2.67M0.00N/AN/A($11.55) per share0.00PBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/ATTOOT2 Biosystems$7.68M0.02N/AN/A($6.91) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/AOPGNOpGen-$32.67MN/A0.00N/AN/A-1,140.36%N/A-287.58%11/13/2025 (Estimated)PBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%11/12/2025 (Estimated)TTOOT2 Biosystems-$50.08MN/A0.00∞N/A-563.16%N/A-174.06%10/6/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVTAInvitaeN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVTAInvitaeN/A2.392.25OPGNOpGenN/A5.455.45PBLAPanbela TherapeuticsN/A0.260.26TTOOT2 BiosystemsN/A0.400.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVTAInvitae61.28%OPGNOpGen2.68%PBLAPanbela Therapeutics4.37%TTOOT2 Biosystems23.18%Insider OwnershipCompanyInsider OwnershipNVTAInvitae0.74%OPGNOpGen43.80%PBLAPanbela Therapeutics0.01%TTOOT2 Biosystems0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVTAInvitae1,700267.01 million284.37 millionOptionableOPGNOpGen10010.07 million4.70 millionNot OptionablePBLAPanbela Therapeutics64.86 million4.86 millionNot OptionableTTOOT2 Biosystems18021.04 million21.04 millionOptionableNVTA, OPGN, TTOO, and PBLA HeadlinesRecent News About These CompaniesTTOO T2 Biosystems, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comT2 Biosystems Inc. (TTOO) After Hours QuoteJune 10, 2025 | nasdaq.comDespite Promising Technology, Did Operational Cost Structure Take Down T2 Biosystems?March 5, 2025 | 360dx.com3T2 Biosystems initiates major layoffs, seeks asset saleFebruary 22, 2025 | uk.investing.comMedical diagnostics firm T2 Biosystems cuts ‘substantially all’ workersFebruary 18, 2025 | bizjournals.comT2 Biosystems to be delisted from NasdaqFebruary 11, 2025 | msn.comT2 Biosystems stock plunges to 52-week low of $0.22January 30, 2025 | msn.comT2 Biosystems Inc’s Stock Drama: Could This Be a Game-Changer for TTOO Investors?January 24, 2025 | bovnews.comBT2 Biosystems stock plunges to 52-week low of $0.25January 21, 2025 | msn.comT2 Biosystems amends loan terms, extends maturity dateJanuary 18, 2025 | msn.comT2 Biosystems reports preliminary Q4 revenue $2.3MJanuary 7, 2025 | markets.businessinsider.comT2 Biosystems Reports Preliminary Financial Results For Q4 And Full Year 2024January 7, 2025 | markets.businessinsider.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial ResultsJanuary 7, 2025 | finance.yahoo.comT2 Biosystems Enhances Governance and Leadership StabilityJanuary 3, 2025 | tipranks.comT2 Biosystems announces sale of four T2Dx Intruments to European distributorDecember 18, 2024 | markets.businessinsider.comT2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European DistributorDecember 18, 2024 | finance.yahoo.comT2 Biosystems achieves milestone with 250,000th novel sepsis test shippedDecember 17, 2024 | markets.businessinsider.comT2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped GloballyDecember 17, 2024 | markets.businessinsider.comT2 Biosystems extends multi-year supplier agreement with VizientDecember 16, 2024 | markets.businessinsider.comT2 Biosystems Extends Supplier Agreement with Vizient Through March 2026 for Rapid Sepsis Detection ProductsDecember 16, 2024 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVTA, OPGN, TTOO, and PBLA Company DescriptionsInvitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.OpGen NASDAQ:OPGNOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Panbela Therapeutics NASDAQ:PBLA$0.05 0.00 (0.00%) As of 09/11/2025Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.T2 Biosystems NASDAQ:TTOO$0.0056 +0.00 (+1.82%) As of 09/12/2025 03:13 PM EasternT2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
